Literature DB >> 31673546

The effect of direct-acting antivirals on hepatocellular carcinoma recurrence: still waiting for the turning point.

Gaetano Serviddio1, Rosanna Villani1.   

Abstract

Entities:  

Year:  2019        PMID： 31673546      PMCID： PMC6791973          DOI： 10.21037/hbsn.2019.05.09

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  13 in total

1.  Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.

Authors:  J C Sheu; J L Sung; D S Chen; P M Yang; M Y Lai; C S Lee; H C Hsu; C N Chuang; P C Yang; T H Wang
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

2.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

3.  A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.

Authors:  Ming-Lung Yu; Shi-Ming Lin; Wan-Long Chuang; Chia-Yen Dai; Jing-Houng Wang; Sheng-Nan Lu; I-Shyan Sheen; Wen-Yu Chang; Chuan-Mo Lee; Yun-Fan Liaw
Journal:  Antivir Ther       Date:  2006

4.  Association between hepatitis C and hepatocellular carcinoma.

Authors:  Luis Jesuino de Oliveria Andrade; Argemiro D'Oliveira; Rosangela Carvalho Melo; Emmanuel Conrado De Souza; Carolina Alves Costa Silva; Raymundo Paraná
Journal:  J Glob Infect Dis       Date:  2009-01

5.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

Authors:  Fabio Conti; Federica Buonfiglioli; Alessandra Scuteri; Cristina Crespi; Luigi Bolondi; Paolo Caraceni; Francesco Giuseppe Foschi; Marco Lenzi; Giuseppe Mazzella; Gabriella Verucchi; Pietro Andreone; Stefano Brillanti
Journal:  J Hepatol       Date:  2016-06-24       Impact factor: 25.083

6.  Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Peter Richardson; Jennifer Kramer
Journal:  Hepatology       Date:  2016-04-19       Impact factor: 17.425

7.  All-Cause Mortality and Progression Risks to Hepatic Decompensation and Hepatocellular Carcinoma in Patients Infected With Hepatitis C Virus.

Authors:  Fujie Xu; Anne C Moorman; Xin Tong; Stuart C Gordon; Loralee B Rupp; Mei Lu; Eyasu H Teshale; Philip R Spradling; Joseph A Boscarino; Connie M Trinacty; Mark A Schmidt; Scott D Holmberg; Scott D Holmberg; Eyasu H Teshale; Philip R Spradling; Anne C Moorman; Jim Xing; Xin Tong; Fujie Xu; Stuart C Gordon; David R Nerenz; Mei Lu; Lois Lamerato; Yan Wang; Loralee B Rupp; Nonna Akkerman; Nancy Oja-Tebbe; Talan Zhang; Jia Li; Alexander Sitarik; Dana Larkin; Joseph A Boscarino; Zahra S Daar; Patrick J Curry; Robert E Smith; Vinutha Vijayadeva; John V Parker; Mark A Schmidt; Judy L Donald; Erin M Keast
Journal:  Clin Infect Dis       Date:  2015-09-28       Impact factor: 9.079

8.  Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.

Authors:  Zoe Mariño; Anna Darnell; Sabela Lens; Victor Sapena; Alba Díaz; Ernest Belmonte; Christie Perelló; Jose Luis Calleja; Maria Varela; Manuel Rodriguez; Carlos Rodriguez de Lope; Susana Llerena; Xavier Torras; Adolfo Gallego; Margarita Sala; Rosa María Morillas; Beatriz Minguez; Jordi Llaneras; Susana Coll; José Antonio Carrion; Mercedes Iñarrairaegui; Bruno Sangro; Ramón Vilana; Manel Sole; Carmen Ayuso; José Ríos; Xavier Forns; Jordi Bruix; María Reig
Journal:  J Hepatol       Date:  2019-01-24       Impact factor: 25.083

Review 9.  Cancer and liver cirrhosis: implications on prognosis and management.

Authors:  Matthias Pinter; Michael Trauner; Markus Peck-Radosavljevic; Wolfgang Sieghart
Journal:  ESMO Open       Date:  2016-03-17

10.  DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.

Authors:  Rosanna Villani; Antonio Facciorusso; Francesco Bellanti; Rosanna Tamborra; Annamaria Piscazzi; Matteo Landriscina; Gianluigi Vendemiale; Gaetano Serviddio
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.